Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Venetoclax and Azacitidine in Newly Diagnosed AML
NCT05048615Phase 2Completed
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Started Jul 2021; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05048615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048615.